Lonsurf works differently than most chemotherapy drugs, and “working” often looks different than you might expect. Rather than shrinking tumors dramatically, Lonsurf’s primary goal is to slow or stop cancer growth and help you live longer. Only about 1.6% of patients in the landmark clinical trial saw their tumors shrink significantly, yet 44% achieved what oncologists call disease control, meaning their cancer stabilized or improved. Understanding what success actually looks like with this drug can help you make sense of your scan results, lab work, and how you feel day to day.
What “Working” Means for Lonsurf
Lonsurf (trifluridine/tipiracil) gets incorporated directly into the DNA of cancer cells, disrupting their ability to replicate. This mechanism tends to hold cancer in place rather than produce the dramatic tumor shrinkage seen with some earlier-line treatments. For patients with metastatic colorectal cancer or metastatic gastric cancer, the realistic goal is stable disease: keeping tumors from growing while maintaining quality of life.
In the pivotal RECOURSE trial, progression-free survival was 2.0 months with Lonsurf compared to 1.7 months with placebo, and overall survival improved meaningfully. Those numbers may sound modest, but they reflect a population that had already exhausted other treatment options. Stable disease in this context is genuinely a win.
Imaging Scans Are the Most Reliable Measure
CT scans are the gold standard for determining whether Lonsurf is controlling your cancer. Clinical experts recommend scans every 2 to 3 months, typically after every 2 to 3 treatment cycles. Your oncologist will compare tumor measurements using standardized criteria called RECIST, which categorize your response as complete response, partial response, stable disease, or progressive disease.
If your scan shows stable disease, that counts as success with Lonsurf. The tumors haven’t grown, and the drug is doing its job. You should not be discouraged if scans don’t show tumors shrinking, since fewer than 2% of patients in trials experienced that kind of response. What matters is that the cancer isn’t advancing.
Tumor Markers Can Offer Clues Between Scans
If you had elevated CEA (carcinoembryonic antigen) levels before starting Lonsurf, your oncologist will likely check this blood marker at least once every 4 weeks. A declining CEA trend generally suggests the treatment is having an effect, and patients with a CEA response tend to have better outcomes overall.
There are important caveats, though. CEA can occasionally drop even when cancer is progressing, and it can rise temporarily for reasons unrelated to tumor growth. A CEA increase on two consecutive blood draws taken at least 2 months apart is considered a strong signal of disease progression, but a single elevated reading doesn’t necessarily mean the drug has stopped working. Scans always take priority over CEA when the two tell conflicting stories. If your cancer doesn’t produce CEA (some cases don’t), this marker won’t be useful for you at all.
Side Effects That May Signal the Drug Is Active
This is one of the more counterintuitive aspects of Lonsurf: certain side effects, particularly low white blood cell counts (neutropenia), appear to be a sign that the drug is being absorbed and incorporated into your cells effectively. The same mechanism that damages cancer cell DNA also affects rapidly dividing blood cells, so a drop in white blood cells suggests the active ingredient is reaching therapeutic levels in your body.
Analysis of the RECOURSE trial found that patients who developed significant neutropenia during their first two treatment cycles had longer overall survival, longer progression-free survival, and maintained their physical functioning for a longer period compared to patients who didn’t develop neutropenia. Neutropenia during any cycle was an independent predictor of better outcomes. In other words, higher drug exposure leads to both more blood count suppression and more anti-tumor activity.
This doesn’t mean you should hope for severe side effects. Your oncologist will monitor your blood counts closely and may adjust your dose or timing if neutropenia becomes dangerous. But if your counts do dip, it’s worth knowing that this is actually a reassuring sign that the drug is pharmacologically active.
How You Feel Day to Day
Quality-of-life data from real-world studies show that patients on Lonsurf report significantly less physical distress, less psychological distress, and less interference with daily activities compared to patients receiving supportive care alone. In one study, 70% of patients on Lonsurf rated their overall quality of life as excellent, good, or moderately good, compared to just 27% of those not on active treatment. Patients on Lonsurf also reported fewer problems with appetite, fatigue, sleep, anxiety, and concentration.
Pay attention to your cancer-related symptoms specifically. If the symptoms that bothered you most before treatment, such as abdominal pain, bloating, fatigue, or bloody stools, are stable or improving, that’s a practical signal that the cancer isn’t advancing. Some patients and caregivers who have used Lonsurf report that it feels more tolerable than their previous treatments, with fewer side effects that disrupt everyday life and an overall improvement in physical condition.
Weight stability is another useful indicator. Unintended weight loss often accompanies progressing cancer, so maintaining your weight (or regaining lost weight) while on Lonsurf suggests the disease is being held in check.
Signs the Drug May Not Be Working
The clearest sign is a scan showing tumor growth or new lesions. Beyond imaging, watch for a return or worsening of cancer symptoms: increasing pain, new pain in different locations, unexplained weight loss, worsening fatigue that goes beyond normal treatment side effects, or a steadily rising CEA level confirmed on repeat testing. Your oncologist will typically reassess your treatment plan if two consecutive scans or two CEA draws two months apart show progression.
It’s worth noting that some patients feel worse initially due to treatment side effects like nausea or fatigue, which can be hard to distinguish from cancer progression. The key difference is timing. Treatment side effects tend to follow a predictable pattern tied to your dosing schedule (Lonsurf is taken for 5 days on, 2 days off, repeated twice, then 2 weeks off), while cancer progression produces symptoms that worsen steadily regardless of when you take the medication.
Putting It All Together
No single indicator tells the whole story. Your oncologist is looking at a combination of scan results, CEA trends, blood counts, and how you’re feeling physically. The timeline matters too. You likely won’t have a clear picture until after your first set of scans at the 8 to 12 week mark. Before that, your blood work and symptom patterns provide the best early signals. If your white blood cell counts dip during the first couple of cycles, your CEA is stable or declining, and your day-to-day symptoms aren’t worsening, those are all encouraging signs that Lonsurf is doing what it’s designed to do: keeping your cancer from moving forward.